Virantmycin, a novel chlorine-containing antiviral antibiotic, has been isolated from Streptomyces nitrosporeus No. AM-2722. The active substance in culture broth is isolated as colorless needles by solvent extraction followed by high performance liquid chromatography on silicic acid. The molecular formula is C18H26NO3C1 (molecular weight 351) from the elemental analysis and mass spectrum. The antibiotic possesses antifungal activity and potent inhibitory activity against various RNA and DNA viruses.
In the course of our screening program for IFN (interferon) inducers and antiviral substances from Streptomyces, we found that Streptomyces sp. No. AM-2722, isolated from the putrefied tissue portion of a pumpkin, produces a novel antibiotic possessing a potent inhibitory activity against both RNA and DNA viruses.') The antibiotic also shows weak antifungal activity. The antibiotic, named virantmycin, is a novel antiviral antibiotic containing chlorine. The structure of virantmycin has been reported elsewhere.') In this paper, we describe the taxonomy of the producing strain, and the production, isolation and physicochemical and biological properties of virantmycin.
Taxonomic Studies
Strain AM-2722 was isolated from a pumpkin spoiled by microorganisms.
The strain was cultivated at 27°C for 14 days on various media such as yeast extract-malt extract agar, inorganic saltsstarch agar, glucose -asparagine agar and tyrosine agar. Its morphological characteristics were examined with both optical and electron microscopes. The sporophores are rectus flexibilis type and have more than ten spores per chain. Conidia with smooth surface are oval (0.4 0.5 x 1.0' 1.1 s) as shown in Fig. 1 . No sclerotic granules, sporangia or zoospores were observed. The characteristics of cultures incubated at 27°C for 14 days are shown in Table 1 . The physiological properties and utilization of carbon sources are summarized in Tables 2 and 3 The antibiotic was assayed by the plaque reduction method with vesicular stomatitis virus (VSV) as an indicator and detected chemically on silica gel thin-layer chromatograms (Kiesel gel 60 F214) of the solvent extract from the whole broth. The virantmycin content in the whole broth was determined by using analytical liquid chromatography with a ,uBondapak C18 column (solvent: MeOH -H20 -HOAc, 80:
20: 5 (v/v), flow rate: 1 ml/minute, detector: UV at 300 nm) for the ethyl acetate extract from the whole broth at pH 3. The time course of virantmycin production detected by the application of analytical liquid chromatography is shown in Fig. 2 . The production of virantmycin in the fermentation broth reached a maximum at about 40 hours and decreased moderately beyond 40 hours.
Isolation and Purification
The isolation procedure for virantmycin is summarized in Scheme 1. The broth was acidified with cone. hydrochloric acid to pH 3.0 and centrifuged with the aid of a Sharpless centrifuge. The wet mycelial cake was suspended in methanol with stirring. The methanol extract was concentrated in vacuo to a brownish syrup. On the other hand, the broth supernatant was extracted twice with ethyl acetate. The extract was concentrated in vaccro to dryness to obtain an oily substance. The crude materials obtained from the broth supernatant and the mycelia were combined. A solution of the crude material in the solvent mentioned below was subjected to preparative liquid chromatography (Prep LC/System 500) on silica gel (2 packed silica gel columns, 300 g x 2) using a mixture of chloroform and methanol (30: 1, v/v) with flow rate at 250 ml/minute under 30 atmospheres. Elution of virantmycin was followed by examining Some physicochemical properties of virantmycin are listed in Table 4 The IR spectrum in carbon tetrachloride showed absorption bands characteristic of a carboxylic acid (vNU 3440 cm-1 and voo 1690 cm-1) and chlorine (627 cm-1). The 1H NMR spectrum in CDCI,, as shown in Fig. 4 showed the presence of three tert-methyl groups (1 1.62), a methoxy group (o 3.4), three aromatic protons (6 6.56, 7.78 and 7.82) and a carboxyl proton (0 8.0). The 13C NMR spectral analysis of virantmycin indicated the existence of a benzoic acid skeleton, a double bond, a methoxymethylene, three methylenes, three methyls, a methine and a quarternary carbon. The structure of the antibiotic has been determined by chemical degradation and spectrometric means, as shown in Fig. 5 .
Biological Properties
The antiviral activity of the antibiotic was assayed by a plaque reduction test.
Materials and Methods
Primary chick embryonic (CE) cells were prepared by trypsinizing 9 days old chick embryos and cultivated in 3 ml of minimum essential medium (MEM) supplemented with 10 % calf serum (CS) in 40 tnm glass dishes. Rabbit continuous cell line RK-13 cells were also cultivated with MEM-CS 10%.
Egypt Ar 339 strain of Shindbis virus (SbV), McMILLAN strain of Western equine encephalitis virus (WEE), DIE strain of vaccinia virus (Vac-DIE), IHD strain of vaccinia virus (Vac-IHD), HF strain of Plaque reduction test of virantmycin on several RNA and DNA viruses was carried out as follows. Primary CE cells were prepared as described in Materials and Methods. Cells were treated with 0.001 -10 tag/ml of virantmycin at 37°C for 20 hours. Virantmycin was removed and cells were infected with 100 PFU/dish of each virus. Afterthere, cell cultures were subjected to the method of plaque formation').
Percentage of plaque reduction was calculated by following formula: _Plaque count (control) -Plaque count (virantmycin) Pl aque count (control) X 100 Newcastle disease virus (NDV) were propagated as described previously."
Plaque formation of viruses and plaque reduction test of virantmycin were carried out as described previously.')
Results and Discussions
As seen in Table 5 , virantmycin inhibited plaque formation by several RNA and DNA viruses at low concentrations. It should be noted that virantmycin inhibits the growth of both RNA and DNA viruses which differ from each other in their growth mechanism. Furthermore, it is a question of interest as to whether the mechanism of action as the same for both types of virus.
The influence on the one step growth of VSV in RK-13 cells treated with virantmycin was investigated as follows.'' Monolayers of RK-13 cells were incubated in the presence or absence of 10 jig/ml of virantmycin in MEM CS 2 % at 37°C for 20 hours (pre-treatment).
Medium was removed and the cells were infected with VSV at an input of multiplicity of infection (m.o.i.), 10 PFU (plaque forming unit) per cell. Ten jig/ml of virantmycin was added to some cultures at the same time and cells were incubated for 1 hour. The inocula were removed and the infected cells were washed three times with phosphate-buffered saline and fed with fresh MEM CS 2 % with or without 10,ag/ml of virantmycin (posttreatment). Cells were further incubated and the cultured fluids were aliquoted at indicated times to assay the growth of virus in each culture.
Representative results are shown in Fig. 6 . In the control culture to which no virantmycin was In the virantmycin preplus post-treated culture, much more reduction in virus release was observed. From these results, virantmycin apparently inhibits the one step growth of VSV. Both pre-and post-treatment of the antibiotic showed suppression of the growth of the virus, however, the persistency of the antibiotic action seemed to be no longer than about 8 hours after the antibiotic was removed.
Virantmycin also posseses weak antifungal activity. The minimum inhibitory concentration (itg/ ml) of the antibiotic is shown in Table 6 . Potato glucose agar, 27°C, 2-4 days.
